SCHEMBL19639673

SCHEMBL19639673

CNC12CC(CN(C)C)(C1)C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL19639639 0.98
SCHEMBL19661154 0.70 SMN1; SMN2 (0.31)
SCHEMBL27412363 0.69
SCHEMBL16450714 0.67 GRIN2D (0.42)
SCHEMBL19566928 0.67 GRIN2D (0.42)
SCHEMBL19661259 0.65
SCHEMBL20715857 0.65
SCHEMBL27412365 0.65
SCHEMBL19661176 0.65
SCHEMBL25127020 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12049460-B2 EGFR inhibitor compounds RECURIUM IP HOLDINGS, LLC (US) 2024-07-30 US disclosed
EP-3464275-B1 EGFR INHIBITOR COMPOUNDS RECURIUM IP HOLDINGS LLC (US) 2024-05-08 EP disclosed
US-20210395230-A1 EGFR INHIBITOR COMPOUNDS RECURIUM IP HOLDINGS, LLC (US) 2021-12-23 US disclosed
US-20210395230-A1 EGFR INHIBITOR COMPOUNDS RECURIUM IP HOLDINGS, LLC (US) 2021-12-23 US disclosed
US-20200181120-A1 EGFR INHIBITOR COMPOUNDS KALYRA PHARMACEUTICALS, INC. 2020-06-11 US disclosed
US-20200181120-A1 EGFR INHIBITOR COMPOUNDS KALYRA PHARMACEUTICALS, INC. 2020-06-11 US disclosed
US-20170342055-A1 EGFR INHIBITOR COMPOUNDS RECURIUM IP HOLDINGS, LLC 2017-11-30 US disclosed
US-20170342055-A1 EGFR INHIBITOR COMPOUNDS RECURIUM IP HOLDINGS, LLC 2017-11-30 US disclosed
WO-2017205459-A1 EGFR INHIBITOR COMPOUNDS KALYRA PHARMACEUTICALS, INC. (US) 2017-11-30 WO disclosed